Antidepressants and Metabolic Disturbances

In a nutshell

Antidepressant-induced weight gain affects 40–65% of patients. The highest-risk agents include mirtazapine, paroxetine, and TCAs. Bupropion and fluoxetine have the strongest evidence for favorable weight profiles, while newer multimodal agents (vortioxetine, vilazodone) also show promise. However, comparisons are constrained by methodological limitations.

• Key clinical recommendations:
  • Agent selection: Prioritize low-risk antidepressants—bupropion (most favorable evidence) and fluoxetine for established options, or vortioxetine, vilazodone, and trazodone when weight is a concern
  • Early monitoring: Monitor weight/BMI/waist every 2–4 weeks for the first 12 weeks, then every 1–3 months
  • Intervention threshold: ≥5% weight change at 4 weeks predicts long-term trajectory and should prompt consideration of switching or adjunctive strategies
  • Management:
    • Switching: Change to a lower-risk agent when clinically significant weight gain occurs
    • Dose reduction: Consider reducing the current dose if depression control allows
    • Pharmacological adjuncts: When switching is not feasible, metformin or GLP-1 agonists can be considered

• When and what to monitor:
  • Monitor weight/BMI/waist every 2–4 weeks for 12 weeks, then every 1–3 months
  • The first month predicts long-term trajectory—≥5% weight change at 4 weeks should prompt intervention
  • Weight gain typically emerges by months 2–3; >80% of gainers show increases by month 3
• Patient factors that amplify risk:
  • Younger men (especially under 50)
  • Family history of obesity
  • Recent pre-treatment weight loss (rebound potential)
  • BMI extremes (low or high) or large waist circumference
  • Emotional eating patterns or carbohydrate cravings
  • Concomitant antipsychotic therapy

Introduction

• This guide provides a synthesis to clarify which agents carry greater metabolic risk, who is most vulnerable, and when risk accrues—translated into actionable strategies.

Epidemiology of Weight Gain

• Weight gain affects 40–65% of patients on antidepressants ^[1,2]
• This can emerge during both acute and maintenance treatment phases ^[1–4]
• In psychiatric outpatients, 55% reported weight gain and 41% met a ≥7% threshold, which underscores the point-of-care burden ^[5]

Clinical Impact

• Cardiometabolic risk: Antidepressant-induced weight gain compounds existing cardiometabolic vulnerability ^[1,6,7]
  • Weight gain on treatment can exacerbate obesity, diabetes, and cardiovascular disease in populations that already have 2–3× higher cardiometabolic disease prevalence than the general population ^[2,8–10]
• Nonadherence: Weight gain is a major driver of treatment discontinuation ^[1,6,7]

Metabolic Risk

• Antidepressant use has been associated with an increased risk of incident type 2 diabetes ^[11–13]
  • Weight gain is probably the most relevant determinant of diabetes through the induction of insulin-resistance ^[11]
• The bidirectional relationship between depression and metabolic syndrome creates a “double-hit” scenario ^[14,15]
  • Depression independently increases odds of metabolic syndrome ^[14]
  • Antidepressant use itself is associated with over 2-fold higher odds of metabolic syndrome, independent of depressive symptoms ^[14]

Mechanisms of Antidepressant-Induced Weight Gain

• The mechanisms for weight gain or metabolic disruption are multifactorial, stemming from the actions of these drugs on systems regulating appetite, satiety, and energy metabolism ^[2]

Overview: Neurotransmitter Pathways and Weight Effects

Histamine H1 receptor antagonism

• High affinity for the histaminergic H1 receptor is strongly correlated with ^[1,2,16]
  • Increased appetite
  • Reduced satiety
  • Increased carbohydrate craving
• The strength of this effect is often dose-dependent and linked to the drug’s binding affinity for the H1 receptor.
• Tricyclic antidepressants (TCA, like amitriptyline) and mirtazapine are notable for their H1 antagonism, which significantly contributes to their weight-gaining effects ^[1,2,16]
• Some SSRIs, such as paroxetine and citalopram, exhibit higher levels of interaction with the histaminergic system, contributing to more pronounced weight gain ^[16]

Muscarinic receptor antagonism

• Muscarinic acetylcholine receptor blockade can also increase appetite ^[1]
• Paroxetine presents anticholinergic properties that may contribute to weight gain
• M3 receptor dysfunction has been associated with impaired insulin-secretory response to hyperglycemia ^[2,16,17]

Serotonin system modulation

• Acute effects (5-HT2C agonism)
  • In the short term, increasing synaptic serotonin levels via reuptake inhibition stimulates postsynaptic 5-HT2C receptors in the hypothalamus.
  • Activation of 5-HT2C receptors on proopiomelanocortin (POMC) neurons has an anorexigenic effect, enhancing satiety, reducing impulsivity, and decreasing food intake ^[1,2]
    • This explains the initial weight neutrality or even modest weight loss observed with many SSRIs, such as fluoxetine, during the first few months of treatment
• Chronic effects (5-HT2C downregulation)
  • With prolonged treatment (after 6–12 months), chronic stimulation of 5-HT2C receptors can lead to their desensitization and downregulation ^[1]
    • This loss of 5-HT2C-mediated satiety signaling unmasks other weight-promoting effects, leading to a gradual increase in appetite, carbohydrate cravings, and subsequent weight gain.
  • This biphasic pattern—initial weight loss or stability followed by long-term weight gain—is particularly pronounced with agents like paroxetine, which also possesses mild anticholinergic and H1-antagonistic properties ^[1,2]
• 5-HT2C antagonism
  • Antagonism of the 5-HT2C receptor, such as by mirtazapine, suppresses satiety (or induces hyperphagic behavior) and is associated with glucose intolerance and insulin resistance ^[1,2,16]

Norepinephrine system modulation

• Noradrenergic effects promote weight neutrality or weight loss by converting fat into heat and energy via beta-3 adrenoceptors in adipose tissue ^[1,16]
• Alpha-2 adrenergic receptor stimulation also has an orexigenic effect ^[18]
• Stimulation of α1 adrenergic receptors leads to an increase in glycemia and stimulation of α2 adrenergic receptors leads to a decrease in glycemia ^[16]
• SNRIs may initially have a small weight-loss effect, followed by weight gain with prolonged use ^[1]
• Duloxetine and venlafaxine can show varied effects, with duloxetine sometimes associated with more pronounced weight gain ^[16]

Dopamine system modulation

• Dopamine serves as a central mediator of reward-driven feeding behaviors and energy homeostasis through its regulatory effects on the hypothalamic melanocortin system ^[1]
  • Enhanced dopaminergic neurotransmission activates melanocortin pathways, promoting satiety and energy expenditure ^[19,20]
  • Diminished dopaminergic tone correlates with increased adiposity ^[19,20]
• This dual nature of dopaminergic influence explains why antidepressants that enhance dopamine transmission (such as bupropion) can promote weight loss
• Reduced dopaminergic tone is observed in obesity, and dopamine D2 receptor blockade can lead to hyperphagia ^[1,16]

Hormonal and metabolic changes

• Antidepressant-induced weight gain is considered the most relevant determinant of diabetes risk due to the induction of insulin resistance ^[11]
  • SSRIs, TCAs, and Mirtazapine have been linked to developing insulin resistance and related metabolic disorders ^[11,21]
• Leptin and ghrelin dysregulation:
  • Antidepressants can also dysregulate leptin and ghrelin levels, regulatory peptides involved in satiety.
    • TCA use (amitriptyline) has been suggested to cause leptin resistance, leading to increases in serum leptin levels and BMI ^[22]
    • Fluoxetine may increase the sensitivity of leptin receptors ^[23]

Peripheral Effects

• Some antidepressants may induce weight change through peripheral mechanisms
  • Some MAOIs can cause hypoglycemia, which stimulates hunger and increases caloric intake ^[24]
  • Phenelzine has also been shown to alter adipocyte differentiation, suggesting that weight gain may result from aberrant metabolic processes rather than solely increased food intake ^[25]

Comparing Weight Gain Risk Across Antidepressants

• Antidepressants can be stratified into risk categories for weight gain ^[1]
  • High risk: >7% weight gain and ≥1.5 kg increase in acute/long-term treatment
  • Moderate risk: >7% weight gain and 0.5-1.4 kg increase
  • Low risk: Weight loss or neutral effects in both acute and long-term treatment, with classification supported by expert opinion
• This stratification can be viewed as a risk continuum

High-Risk Agents

• Avoid mirtazapine, most TCAs, phenelzine, and paroxetine in patients with obesity, prediabetes/T2DM, or strong weight-sensitive priorities when reasonable alternatives exist.

Mirtazapine

• Risk level:
  • Mirtazapine is consistently associated with significant weight gain, often occurring rapidly after treatment initiation ^[1]
• Magnitude of weight gain:
  • Acute treatment (4–12 weeks) shows an average weight gain of +1.74 kg; long-term use (  ≥ 4 months) shows an average gain of +2.59 kg ^[2,26]
  • High prevalence of ≥7% gain in a cross-sectional study ^[5]
  • Mirtazapine showed the highest incidence rate ratio (IRR) for ≥5% weight gain among antidepressants (adjusted IRR ≈1.50) across a 10-year UK primary-care cohort ^[27]
• Mechanisms:
  • Its appetite-stimulating effect is driven by a potent dual antagonism of histamine H1 and serotonin 5-HT2C receptors ^[1]
  • Blockade of the 5-HT2A receptor also leads to excessive NPY release and disinhibition of orexigenic signaling ^[16,28]
• Clinical considerations:
  • Consider for underweight patients or when stimulating appetite is clinically indicated

Amitriptyline

• Risk level:
  • TCAs are commonly associated with a high risk of weight gain during both acute and long-term exposure ^[1]
  • TCAs predispose individuals to metabolic syndrome independent of depressive symptom severity ^[29]
  • Amitriptyline and its metabolite, nortriptyline, have the greatest documented weight-gain effects ^[1]
• Magnitude of weight gain:
  • Short-term treatment (4-12 weeks): Mean weight gain: +1.52 kg ^[26,30]
  • Long-term treatment (> 12 weeks): Mean weight gain: +2.24 kg ^[1]
  • Weight gain tends to be progressive with continued treatment ^[31]
• Mechanisms:
  • Potent histamine H1 antagonism with orexigenic effect ^[1,2]
  • Anticholinergic effects contributing to metabolic dysregulation
• Clinical considerations:
  • Weight gain potential: Amitriptyline > Clomipramine > Imipramine ^[31,32]
  • If TCA needed and weight is a concern, consider imipramine as a more weight-sparing alternative within the class ^[26,31]

Nortriptyline

• Risk level:
  • High ^[1].
• Magnitude of weight gain ^[1,26]
  • Short-term treatment (4-12 weeks): Mean weight gain: +2.0 kg
  • Long-term treatment (> 12 weeks): Mean weight gain: +1.24 kg
• Mechanisms:
  • Similar to amitriptyline (H1 and anticholinergic pathways)

Paroxetine

• Risk level:
  • Highest weight-gain potential among SSRIs ^[1]
• Magnitude of weight gain:
  • +0.37 kg at 6 months vs Sertraline in a target-trial emulation across new users ^[7]
  • Higher risk of ≥5% gain at 6 mo, significant weight gain (+2.73 kg) following long-term use ^[26]
  • 13% of patients gained >7% body weight at 9 months, with mean gains of 2.49 kg at 2 years ^[33]
• Mechanisms:
  • 5-HT2C downregulation with H1/anticholinergic burden ^[1,2]
• Clinical considerations:
  • Particularly prone to early weight gain; monitor weight closely in the first month

Phenelzine (MAOIs)

• Risk level:
  • MAOIs, such as Phenelzine, are associated with a high risk of weight gain ^[34–36]
• Magnitude of weight gain:
  • ~43% with mean +9.1 kg at 6 mo in older series ^[37]
• Alternatives within class:
  • Tranylcypromine (irreversible, nonselective MAOI) is more weight-sparing (≈0–4 kg typical change; severe gain uncommon) ^[1,36,38]
  • Moclobemide (reversible inhibitor of MAO-A, RIMA) shows minimal change; may produce slight loss in patients with increased appetite/weight during the depressive episode ^[39]
    • Useful when avoiding weight gain is a priority and an MAO-A agent is appropriate
    • Dietary restrictions are less stringent than with irreversible MAOIs, but interaction vigilance remains essential

Moderate-Risk Agents

• Moderate-risk agents often exhibit weight-neutrality or even weight loss during acute treatment, but carry a measurable risk of weight gain upon long-term exposure

Escitalopram

• Risk level:
  • Escitalopram showed higher 6-month mean gain vs sertraline; overall moderate risk with heterogeneity across studies ^[5,7]
• Magnitude of weight gain:
  • +0.41 kg at 6 mo vs sertraline (largest SSRI mean difference, but small absolute value) ^[7]
    • 15% greater risk of ≥5% gain at 6 months compared to sertraline ^[7]
  • ≥7% gain observed in ~49% in one series vs 20% on sertraline ^[5]
• Potential mechanism:
  • Despite being pharmacologically similar to citalopram, escitalopram shows a distinctly higher weight gain profile ^[1,16]
  • Possibly due to greater serotonin transporter binding affinity, resulting in more pronounced 5-HT2C receptor downregulation over time ^[1,16]

Citalopram

• Risk level:
  • Citalopram has been associated with significant weight gain with long-term use
• Magnitude of weight gain:
  • Weight gain ranges from +1.69 kg at 4 months ^[26] to more substantial increases of +2.68 kg by 24 months ^[40]
  • 31.6% of patients experienced ≥7% gain from baseline ^[5]
  • Comparison with sertraline: Mean weight gain at 6 months was +0.12 kg ^[7]
• Clinical considerations:
  • Temporal progression suggests that weight gain risk increases with continued treatment; proactive weight monitoring is recommended ^[1]

Sertraline

• Risk level:
  • Moderate, often exhibiting a biphasic pattern ^[1,41]
  • It is frequently used as a reference agent in comparative studies ^[7]
• Magnitude of weight gain:
  • Acute treatment (4-12 weeks): Associated with initial weight-neutrality or slight weight loss (~-0.87 kg) ^[1,26]
  • Long-term treatment:
    • This trend typically reverses, leading to moderate weight gain ^[1]
    • Long-term use was associated with a mean gain of +4.76 kg at 24 months in one cohort ^[40], and a 20.0% prevalence of ≥7% weight gain was observed in one cross-sectional study ^[5]
• Mechanism:
  • The biphasic pattern is hypothesized to result from an initial serotonergic anorexigenic effect, followed by the eventual downregulation of 5-HT2C receptors, which diminishes this effect ^[1,16]

Duloxetine

• Risk level:
  • Generally causes short-term weight loss (-0.55 kg) but can lead to long-term gain ^[1,26,33]
• Magnitude of weight gain:
  • Comparison with sertraline: Mean weight gain at 6 months was +0.34 kg ^[7]
  • 33.3% of patients experienced ≥7% weight gain from baseline ^[5]
  • 10-15% greater risk of ≥5% gain at 6 months compared to sertraline ^[7]

Venlafaxine

• Risk level:
  • Moderate, with a mixed profile that appears weight-neutral acutely but carries a risk for significant gain long-term.
• Magnitude of weight gain:
  • Acute treatment: Associated with weight-neutrality or slight weight loss (~-0.50 kg) ^[1,26]
  • Long-term treatment: Evidence is mixed, with some studies suggesting possible moderate gain ^[33,42] and others reporting below average weight gain ^[1,43]
• Prevalence of significant gain:
  • Despite modest mean changes in some trials, a high prevalence (52.1%) of patients experiencing ≥7% weight gain was reported in one study, comparable to paroxetine (55%) ^[5]
• Clinical consideration:
  • The high prevalence of significant (≥7%) gain warrants close monitoring, even if acute effects are neutral ^[5]
  • Heterogeneous long-term findings limit certainty on the typical long-term trajectory ^[1]

Low-Risk or Weight-Favorable Agents

• Low-risk agents are those generally associated with weight-neutral effects or weight loss, making them favorable options for patients with pre-existing weight concerns

Bupropion

• Risk level:
  • Bupropion is consistently associated with weight loss or neutrality ^[1,2]
• Mechanism:
  • Norepinephrine and dopamine reuptake inhibition (NDRI), which is proposed to suppress appetite and potentially increase energy expenditure ^[1,2]
• Magnitude of weight gain:
  • Short-term: In a 6-month target-trial emulation, mean weight change was −0.22 kg compared to sertraline ^[7]
  • Long-term: Weight remained below the sertraline reference group at 12 and 24 months ^[7]
• Prevalence of significant gain: Associated with the lowest risk of ≥5% gain, showing a 15% reduced risk compared to sertraline initiators ^[7].
• Clinical considerations:
  • Consider bupropion for individuals with obesity and MDD or when weight gain is a concern, absent contraindications ^[1]
  • Bupropion/naltrexone combination therapy is used for chronic weight management in individuals with obesity ^[44,45]
    • Bupropion/naltrexone + counseling reduced depressive symptoms and produced −4.0% (12 weeks) and −5.3% (24 weeks) weight loss in overweight/obese women with MDD ^[46]

Fluoxetine

• Risk level:
  • Generally weight-neutral; small acute weight loss is common, while long-term effects are mixed ^[1]
• Magnitude of weight gain
  • Short-term:
    • RCTs show modest weight loss (~−0.9 kg) versus placebo during acute treatment ^[26,47]
    • Comparison with sertraline: Mean weight change at 6 months was −0.07 kg (not statistically significant) ^[7]
    • Only 6.9% of patients experienced ≥7% weight gain from baseline ^[5]
  • Long-term:
    • May be associated with modest gain; one study reported moderate weight gain after extended use ^[48]
    • Fluoxetine showed the least long-term weight change among SSRIs (approximately +0.7 to +0.8 kg at 9 months) in one medical-record review ^[33]
• Clinical considerations:
  • Fluoxetine shows low acute risk, with initial weight loss, but requires monitoring during long-term treatment as moderate gain may emerge.

Vortioxetine

• Risk level:
  • Vortioxetine generally presents a low incidence of clinically significant weight gain across trials ^[1,49]
• Magnitude of weight gain:
  • Short-term data (6–8 weeks): No significant weight gain versus placebo; no dose-response effect on weight observed ^[1,50]
  • Long-term data (open-label extensions) ^[51]
    • Incidence of weight gain: 3.8% (5–10 mg) and 4.4% (15–20 mg).
    • Mean change: +0.8 kg (5–10 mg) and +0.7 kg (15–20 mg) at study end.
• Clinical consideration:
  • Long-term data are largely from open-label extensions; real-world head-to-head metabolic data remain comparatively limited.

Vilazodone

• Risk level:
  • Generally weight-neutral in clinical studies; adverse-event profiles are similar to placebo with no consistent, clinically meaningful weight change ^[52,53]
• Magnitude of weight gain:
  • Long-term data (1-year open-label) ^[54]
    • Mean weight change: +1.7 kg.
    • Incidence of reported weight gain: 9.5% at study end

Trazodone

• Risk level:
  • Weight-neutral to slight weight loss across clinical studies; low incidence of clinically meaningful gain ^[1,55–57]
• Clinical consideration:
  • May be useful when avoiding weight gain is a priority, especially if insomnia or nighttime agitation co-occur.

Desvenlafaxine

• Risk level:
  • Weight neutrality: Pooled analyses of nine short-term trials (n=1,834) and long-term data (n=594) show no clinically significant weight changes with either 50 mg or 100 mg doses ^[58]
• Magnitude of weight gain:
  • Short-term: Statistically significant but clinically minimal weight reduction (<1 kg) across all BMI categories in a post-hoc analysis ^[59]
  • Long-term: No significant long-term changes in weight were observed ^[59]
• Clinical consideration:
  • Desvenlafaxine may represent a weight-favorable option within the SNRI class.

Levomilnacipran

• Risk level:
  • No significant weight gain reported in short- or long-term trials in a systematic review ^[60]
• Magnitude of weight gain:
  • In a 48-week open-label trial, mean weight change was −0.6 kg; 10% experienced ≥7% increase while 17% experienced ≥7% decrease, suggesting balanced bidirectional effects ^[1,61]
• Clinical consideration:
  • Limited evidence; larger, controlled, and longer-duration studies are needed to fully clarify metabolic safety, but available data suggest a favorable profile.

Patient-Specific Risk Factors for Weight Gain

• The risk of developing antidepressant-induced weight gain is not determined by the drug alone; it is a product of the interaction between the medication and the individual patient.
• Identifying patient-specific factors that confer greater susceptibility is a critical step toward a personalized, preventive approach to management.
• Antidepressant exposure increases the incidence of ≥5% weight gain across all age and BMI strata—routine weight checks are essential for all patients, with tighter intervals when other risk factors are present ^[43]
• Clinical tips:
  • Set tighter early-weight monitoring (every 2–4 weeks for the first 12 weeks) in high-risk patients
  • Favor lower-risk agents when efficacy allows
  • Expect weight change signals by weeks 4–12 and act early

Demographics

• Younger age
  • Younger patients are significantly associated with greater weight gain ^[5]
  • Individuals under 50 years old were more likely to gain weight after antidepressant treatment compared to those over 65 ^[3,62]
• Sex
  • Male sex was associated with greater weight gain during antidepressant treatment in large longitudinal EHR cohorts ^[33]
  • Naturalistic studies suggested female sex was a risk factor for weight gain ^[63]
  • Findings on sex are somewhat mixed depending on the analytic method; in one multivariate logistic regression analysis, sex was not found to be an independent predictor ^[5]
• Lower educational attainment
  • Having fewer years of education was identified as an independent predictor of experiencing ≥7% weight gain following antidepressant usage ^[5]

Family & personal history

• Family history of obesity
  • Ask specifically about parental/sibling obesity
  • A positive family history of obesity was a strong predictor of weight gain, which may suggest potential genetic predisposition to the metabolic effects of antidepressants ^[5]
• Pre-baseline weight trend
  • Patients who experienced weight loss in the 6 months prior to treatment initiation were associated with significantly greater weight gain once antidepressant treatment began ^[33]
  • In some cases, this weight gain may reflect recovery from depression-related weight loss rather than solely a drug side effect ^[3,64]

Anthropometric and metabolic baseline factors

• BMI at baseline shows divergent patterns:
  • Lower baseline BMI predicted ≥7% gain in one study ^[5], while higher pretreatment BMI and larger waist circumference predicted greater gain in other analyses ^[2,65]
• Clinical tip: Treat extremes as high-risk—low BMI (rebound potential) and high BMI/large waist (metabolic susceptibility)

Lifestyle and clinical comorbidity factors

• Dietary patterns
  • The association between SSRI use and weight gain was stronger among those with high intake of a Western dietary pattern ^[62]
• Sedentary lifestyle  ^[62]
• Smoking status  ^[62]
• Emotional eating/cravings
  • Screen briefly at baseline: “Do you eat more with stress? Crave sweets? History of yo-yo dieting?”
  • Patients with emotional eating, cravings for sweets/fast food, and weight-cycling behaviors are associated with higher rates of obesity and metabolic syndrome ^[66]
  • Many patients report craving for carbohydrates and increased appetite following antidepressant administration ^[2]
• Concomitant medications
  • Concomitant antipsychotic therapy amplifies weight gain risk during antidepressant treatment ^[33]
  • Clinical tip: If antipsychotics are necessary, intensify metabolic monitoring and consider selecting antidepressants with lower weight liability
• Early weight change signal
  • The magnitude of weight change observed during the first month of administration is the best predictor of the long-term weight change trajectory ^[2]
  • Weight gain often begins within the first 2–3 months of treatment; >80% of gainers in one series had increases by month 3 ^[5]
  • A ≥5% weight change during this early phase should prompt a change in treatment strategy or incorporation of weight control measures ^[2,67]
  • Early weight gain has also been found to predict later metabolic syndrome development ^[68]

Who is at Highest Risk?

• Younger men (especially under 50)
• Family history of obesity or recent pre-treatment weight loss
• BMI extremes (low or high) or large waist circumference
• Emotional eating/food cravings
• CYP2C19 poor metabolizers (on citalopram/escitalopram)
• Concomitant antipsychotic therapy

Strategies for Mitigating Antidepressant-Induced Weight Gain

Initial Strategies: Agent Selection and Switching

• Selecting an antidepressant with low propensity for weight gain is the most fundamental mitigation strategy
• Prefer bupropion, fluoxetine (weight-loss/neutral), or neutral options (e.g., vortioxetine, vilazodone, trazodone) if weight gain is a concern ^[2]
• Avoid mirtazapine, paroxetine, many TCAs, and some MAOIs in weight-sensitive patients ^[1,7]
• Since weight gain appears to be dose and time-dependent with some antidepressants ^[2], a dose reduction may be considered if depression control allows

Monitoring for Antidepressant-Induced Weight Gain

• Identify high-risk patients at baseline^[2]
  • Patients with lower BMI at treatment onset, family history of obesity, or lower educational status should be followed closely for weight changes
• Baseline metabolic assessment
  • Assessment and monitoring of metabolic syndrome components should be routine for individuals with depressive symptoms taking antidepressant medication ^[14]
  • Include waist circumference, fasting plasma glucose, and HDL-cholesterol
• Focus on the early weight change trajectory
  • The initial phase of treatment is the most critical period for predicting long-term outcomes and necessitating early intervention ^[8]
  • The rate of weight gain during the first month appears to be the best predictor of further weight change trajectory ^[16]
  • Early gain predicts further gain—switch away from higher-risk agents if early gain emerges and depression control allows ^[8]
• Consider intervention when:
  • An increase of ≥7% of baseline body weight, defined as clinically relevant by the FDA ^[3]
  • A weight change of ≥5% compared to baseline at the one-month mark   ^[16,67]

Pharmacological Adjuncts

• For patients requiring higher-risk agents or those who experience weight gain despite optimized selection, adjunctive treatments may be considered

Metformin

• Most widely used for preventing/treating psychotropic-related weight gain ^[2,69]
• Effective in reducing weight gain associated with antidepressant use ^[2,70]
• Dosing: 500–2500 mg/day in divided doses

GLP-1 receptor agonists 

• Effective in mitigating psychotropic-related weight gain ^[71]
• Antidepressant-specific data are limited, but signals are favorable and clinically meaningful in patients with obesity ^[71,72]
• Dosing
  • Liraglutide SC daily: 0.6 mg ×1 week → 1.2 mg ×1 week; consider uptitration to 3.0 mg when obesity-indicated and tolerated ^[71]
  • Exenatide ER SC weekly: 2 mg weekly ^[71]
  • Semaglutide SC weekly: titrate 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg as tolerated when obesity-indicated; psychiatric data are emerging and supportive in psychotropic-treated populations ^[73–75]

Naltrexone/bupropion 

• Combination as an add-on to ongoing antidepressant therapy has been shown to promote weight loss in patients with obesity or who are overweight ^[76]
• Dosing (ER formulation): titrate from 8/90 mg daily to 32/360 mg/day over 4 weeks ^[76]
• May be a useful strategy when mood is controlled but weight trajectory is adverse.

Gut microbiota modulation

• Emerging research suggests synbiotics (probiotics plus prebiotics) may help manage antidepressant-induced weight gain ^[77–79]
• More studies are required to establish clear clinical guidelines

Behavioral and Lifestyle Interventions

• Active body weight management
  • Should accompany antidepressant treatment ^[8]
  • Strategies include dietary modifications (specifically reducing the Western dietary pattern), regular physical activity, and smoking cessation ^[62,80]
• Cognitive-behavioral therapy (CBT)
  • CBT has been shown to be efficacious in managing both obesity and comorbid depression ^[81]

References

• Gill, H., Gill, B., El-Halabi, S., Chen-Li, D., Lipsitz, O., Rosenblat, J. D., Van Rheenen, T. E., Rodrigues, N. B., Mansur, R. B., Majeed, A., Lui, L. M. W., Nasri, F., Lee, Y., & Mcintyre, R. S. (2020). Antidepressant Medications and Weight Change: A Narrative Review. Obesity, 28(11), 2064–2072. https://doi.org/10.1002/oby.22969
• Mouawad, M., Nabipur, L., & Agrawal, D. K. (2025). Impact of Antidepressants on Weight Gain: Underlying Mechanisms and Mitigation Strategies.
• Alonso‐Pedrero, L., Bes‐Rastrollo, M., & Marti, A. (2019). Effects of antidepressant and antipsychotic use on weight gain: A systematic review. Obesity Reviews, 20(12), 1680–1690. https://doi.org/10.1111/obr.12934
• Cartwright, C., Gibson, K., Read, J., Cowan, O., & Dehar, T. (2016). Long-term antidepressant use: Patient perspectives of benefits and adverse effects. Patient Preference and Adherence, 10, 1401–1407. https://doi.org/10.2147/PPA.S110632
• Uguz, F., Sahingoz, M., Gungor, B., Aksoy, F., & Askin, R. (2015). Weight gain and associated factors in patients using newer antidepressant drugs. General Hospital Psychiatry, 37(1), 46–48. https://doi.org/10.1016/j.genhosppsych.2014.10.011
• Ho, S. C., Chong, H. Y., Chaiyakunapruk, N., Tangiisuran, B., & Jacob, S. A. (2016). Clinical and economic impact of non-adherence to antidepressants in major depressive disorder: A systematic review. Journal of Affective Disorders, 193, 1–10. https://doi.org/10.1016/j.jad.2015.12.029
• Petimar, J., Young, J. G., Yu, H., Rifas-Shiman, S. L., Daley, M. F., Heerman, W. J., Janicke, D. M., Jones, W. S., Lewis, K. H., Lin, P.-I. D., Prentice, C., Merriman, J. W., Toh, S., & Block, J. P. (2024). Medication-Induced Weight Change Across Common Antidepressant Treatments. Annals of Internal Medicine, 177(8), 993–1003. https://doi.org/10.7326/M23-2742
• Solmi, M., Miola, A., Capone, F., Pallottino, S., Højlund, M., Firth, J., Siskind, D., Holt, R. I. G., Corbeil, O., Cortese, S., Dragioti, E., Du Rietz, E., Nielsen, R. E., Nordentoft, M., Fusar-Poli, P., Hartman, C. A., Høye, A., Koyanagi, A., Larsson, H., … Correll, C. U. (2024). Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: A state-of-the-art clinical review. Expert Opinion on Drug Safety, 23(10), 1249–1269. https://doi.org/10.1080/14740338.2024.2396396
• Lassale, C., Lugon, G., Hernáez, Á., Frank, P., Marrugat, J., Ramos, R., Garre-Olmo, J., & Elosua, R. (2024). Trajectories of antidepressant use and 6-year change in body weight: A prospective population-based cohort study. Frontiers in Psychiatry, 15, 1464898. https://doi.org/10.3389/fpsyt.2024.1464898
• Compton, M. T., Daumit, G. L., & Druss, B. G. (2006). Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: A preventive perspective. Harvard Review of Psychiatry, 14(4), 212–222. https://doi.org/10.1080/10673220600889256
• Salvi, V., Grua, I., Cerveri, G., Mencacci, C., & Barone-Adesi, F. (2017). The risk of new-onset diabetes in antidepressant users – A systematic review and meta-analysis. PLOS ONE, 12(7), e0182088. https://doi.org/10.1371/journal.pone.0182088
• Andersohn, F., Schade, R., Suissa, S., & Garbe, E. (2009). Long-Term Use of Antidepressants for Depressive Disorders and the Risk of Diabetes Mellitus. American Journal of Psychiatry, 166(5), 591–598. https://doi.org/10.1176/appi.ajp.2008.08071065
• Kivimäki, M., Hamer, M., Batty, G. D., Geddes, J. R., Tabak, A. G., Pentti, J., Virtanen, M., & Vahtera, J. (2010). Antidepressant Medication Use, Weight Gain, and Risk of Type 2 Diabetes. Diabetes Care, 33(12), 2611–2616. https://doi.org/10.2337/dc10-1187
• Crichton, G. E., Elias, M. F., & Robbins, M. A. (2016). Association between depressive symptoms, use of antidepressant medication and the metabolic syndrome: The Maine-Syracuse Study. BMC Public Health, 16(1), 502. https://doi.org/10.1186/s12889-016-3170-2
• Pan, A., Keum, N., Okereke, O. I., Sun, Q., Kivimaki, M., Rubin, R. R., & Hu, F. B. (2012). Bidirectional association between depression and metabolic syndrome: A systematic review and meta-analysis of epidemiological studies. Diabetes Care, 35(5), 1171–1180. https://doi.org/10.2337/dc11-2055
• Kukucka, T., Ferencova, N., Visnovcova, Z., Ondrejka, I., Hrtanek, I., Kovacova, V., Macejova, A., Mlyncekova, Z., & Tonhajzerova, I. (2024). Mechanisms Involved in the Link between Depression, Antidepressant Treatment, and Associated Weight Change. International Journal of Molecular Sciences, 25(8), 4511. https://doi.org/10.3390/ijms25084511
• Larabee, C. M., Neely, O. C., & Domingos, A. I. (2020). Obesity: A neuroimmunometabolic perspective. Nature Reviews. Endocrinology, 16(1), 30–43. https://doi.org/10.1038/s41574-019-0283-6
• van Gestel, M. A., Kostrzewa, E., Adan, R. a. H., & Janhunen, S. K. (2014). Pharmacological manipulations in animal models of anorexia and binge eating in relation to humans. British Journal of Pharmacology, 171(20), 4767–4784. https://doi.org/10.1111/bph.12789
• Lee, S. H., Paz-Filho, G., Mastronardi, C., Licinio, J., & Wong, M.-L. (2016). Is increased antidepressant exposure a contributory factor to the obesity pandemic? Translational Psychiatry, 6(3), e759–e759. https://doi.org/10.1038/tp.2016.25
• Nirenberg, M. J., & Waters, C. (2006). Compulsive eating and weight gain related to dopamine agonist use. Movement Disorders: Official Journal of the Movement Disorder Society, 21(4), 524–529. https://doi.org/10.1002/mds.20757
• Scheen, A. J. (2023). Metabolic disorders induced by psychotropic drugs. Annales D’endocrinologie, 84(3), 357–363. https://doi.org/10.1016/j.ando.2023.03.006
• Berilgen, M. S., Bulut, S., Gonen, M., Tekatas, A., Dag, E., & Mungen, B. (2005). Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia: An International Journal of Headache, 25(11), 1048–1053. https://doi.org/10.1111/j.1468-2982.2005.00956.x
• Scabia, G., Barone, I., Mainardi, M., Ceccarini, G., Scali, M., Buzzigoli, E., Dattilo, A., Vitti, P., Gastaldelli, A., Santini, F., Pizzorusso, T., Maffei, L., & Maffei, M. (2018). The antidepressant fluoxetine acts on energy balance and leptin sensitivity via BDNF. Scientific Reports, 8(1), 1781. https://doi.org/10.1038/s41598-018-19886-x
• Cantú, T. G., & Korek, J. S. (1988). Monoamine Oxidase Inhibitors and Weight Gain. Drug Intelligence & Clinical Pharmacy, 22(10), 755–759. https://doi.org/10.1177/106002808802201002
• Chiche, F., Le Guillou, M., Chétrite, G., Lasnier, F., Dugail, I., Carpéné, C., Moldes, M., & Fève, B. (2009). Antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes. Molecular Pharmacology, 75(5), 1052–1061. https://doi.org/10.1124/mol.108.052563
• Serretti, A., & Mandelli, L. (2010). Antidepressants and body weight: A comprehensive review and meta-analysis. The Journal of Clinical Psychiatry, 71(10), 1259–1272. https://doi.org/10.4088/JCP.09r05346blu
• Gafoor, R., Booth, H. P., & Gulliford, M. C. (2018). Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: Population based cohort study. BMJ (Clinical Research Ed.), 361, k1951. https://doi.org/10.1136/bmj.k1951
• Roerig, J. L., Steffen, K. J., & Mitchell, J. E. (2011). Atypical antipsychotic-induced weight gain: Insights into mechanisms of action. CNS Drugs, 25(12), 1035–1059. https://doi.org/10.2165/11596300-000000000-00000
• van Reedt Dortland, A. K. B., Giltay, E. J., van Veen, T., Zitman, F. G., & Penninx, B. W. J. H. (2010). Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatrica Scandinavica, 122(1), 30–39. https://doi.org/10.1111/j.1600-0447.2010.01565.x
• Abosi, O., Lopes, S., Schmitz, S., & Fiedorowicz, J. G. (2018). Cardiometabolic Effects of Psychotropic Medications. Hormone Molecular Biology and Clinical Investigation, 36(1), /j/hmbci.2018.36.issue-1/hmbci-2017-0065/hmbci-2017-0065.xml. https://doi.org/10.1515/hmbci-2017-0065
• Berken, G. H., Weinstein, D. O., & Stern, W. C. (1984). Weight gain. A side-effect of tricyclic antidepressants. Journal of Affective Disorders, 7(2), 133–138. https://doi.org/10.1016/0165-0327(84)90031-4
• Ranjbar, S. (2013). The Association of Antidepressant Medication and Body Weight Gain. https://www.ojhas.org/issue45/2013-1-1.pdf
• Blumenthal, S. R., Castro, V. M., Clements, C. C., Rosenfield, H. R., Murphy, S. N., Fava, M., Weilburg, J. B., Erb, J. L., Churchill, S. E., Kohane, I. S., Smoller, J. W., & Perlis, R. H. (2014). An Electronic Health Records Study of Long-term Weight Gain Following Antidepressant Use. JAMA Psychiatry, 71(8), 889–896. https://doi.org/10.1001/jamapsychiatry.2014.414
• Cantú, T. G., & Korek, J. S. (1988). Monoamine oxidase inhibitors and weight gain. Drug Intelligence & Clinical Pharmacy, 22(10), 755–759. https://doi.org/10.1177/106002808802201002
• van PRAAG, H., & Leijnse, B. (1963). The influence of some antidepressives of the hydrazine type on the glucose metabolism in depressed patients. Clinica Chimica Acta; International Journal of Clinical Chemistry, 8, 466–475. https://doi.org/10.1016/0009-8981(63)90088-3
• Ricken, R., Ulrich, S., Schlattmann, P., & Adli, M. (2017). Tranylcypromine in mind (Part II): Review of clinical pharmacology and meta-analysis of controlled studies in depression. European Neuropsychopharmacology, 27(8), 714–731. https://doi.org/10.1016/j.euroneuro.2017.04.003
• Evans, D. L., Davidson, J., & Raft, D. (1982). Early and late side effects of phenelzine. Journal of Clinical Psychopharmacology, 2(3), 208–210. https://www.ncbi.nlm.nih.gov/pubmed/7096609
• Wharton, S., Raiber, L., Serodio, K. J., Lee, J., & Christensen, R. A. (2018). Medications that cause weight gain and alternatives in Canada: A narrative review. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 11, 427–438. https://doi.org/10.2147/DMSO.S171365
• Lonnqvist, J., Sihvo, S., Syvälahti, E., & Kiviruusu, O. (1994). Moclobemide and fluoxetine in atypical depression: A double-blind trial. Journal of Affective Disorders, 32(3), 169–177. https://doi.org/10.1016/0165-0327(94)90015-9
• Arterburn, D., Sofer, T., Boudreau, D. M., Bogart, A., Westbrook, E. O., Theis, M. K., Simon, G., & Haneuse, S. (2016). Long-Term Weight Change after Initiating Second-Generation Antidepressants. Journal of Clinical Medicine, 5(4), 48. https://doi.org/10.3390/jcm5040048
• Wang, S.-M., Han, C., Bahk, W.-M., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018). Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review. Chonnam Medical Journal, 54(2), 101–112. https://doi.org/10.4068/cmj.2018.54.2.101
• Masand, P. S., & Gupta, S. (2002). Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists, 14(3), 175–182. https://doi.org/10.1023/a:1021141404535
• Gafoor, R., Booth, H. P., & Gulliford, M. C. (2018). Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: Population based cohort study. BMJ, k1951. https://doi.org/10.1136/bmj.k1951
• ContraveFDA. (n.d.). Retrieved January 27, 2025, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/200063s000lbl.pdf
• Yanovski, S. Z., & Yanovski, J. A. (2015). Naltrexone-Extended Release plus Bupropion-Extended Release for Treatment of Obesity. JAMA, 313(12), 1213–1214. https://doi.org/10.1001/jama.2015.1617
• McElroy, S. L., Guerdjikova, A. I., Kim, D. D., Burns, C., Harris-Collazo, R., Landbloom, R., & Dunayevich, E. (2013). Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: Results of a pilot study. The Primary Care Companion for CNS Disorders, 15(3), PCC.12m01494. https://doi.org/10.4088/PCC.12m01494
• Sansone, R. A., & Sansone, L. A. (2014 Mar-Apr). Serotonin Norepinephrine Reuptake Inhibitors: A Pharmacological Comparison. Innovations in Clinical Neuroscience, 11(3–4), 37. https://pmc.ncbi.nlm.nih.gov/articles/PMC4008300/
• Michelson, D., Amsterdam, J. D., Quitkin, F. M., Reimherr, F. W., Rosenbaum, J. F., Zajecka, J., Sundell, K. L., Kim, Y., & Beasley, C. M. (1999). Changes in weight during a 1-year trial of fluoxetine. The American Journal of Psychiatry, 156(8), 1170–1176. https://doi.org/10.1176/ajp.156.8.1170
• Inoue, T., Nishimura, A., Sasai, K., & Kitagawa, T. (2018). Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial. Psychiatry and Clinical Neurosciences, 72(2), 103–115. https://doi.org/10.1111/pcn.12623
• Food, U. S., & Administration, D. (2023). TRINTELLIX® (vortioxetine) tablets, for oral use Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204447s026lbl.pdf
• Baldwin, D. S., Chrones, L., Florea, I., Nielsen, R., Nomikos, G. G., Palo, W., & Reines, E. (2016). The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. Journal of Psychopharmacology (Oxford, England), 30(3), 242–252. https://doi.org/10.1177/0269881116628440
• Mathews, M., Gommoll, C., Chen, D., Nunez, R., & Khan, A. (2015). Efficacy and safety of vilazodone 20 and 40mg in major depressive disorder: A randomized, double-blind, placebo-controlled trial. International Clinical Psychopharmacology, 30(2), 67–74. https://doi.org/10.1097/YIC.0000000000000057
• Croft, H. A., Pomara, N., Gommoll, C., Chen, D., Nunez, R., & Mathews, M. (2014). Efficacy and safety of vilazodone in major depressive disorder: A randomized, double-blind, placebo-controlled trial. The Journal of Clinical Psychiatry, 75(11), e1291–1298. https://doi.org/10.4088/JCP.14m08992
• Robinson, D. S., Kajdasz, D. K., Gallipoli, S., Whalen, H., Wamil, A., & Reed, C. R. (2011). A 1-year, open-label study assessing the safety and tolerability of vilazodone in patients with major depressive disorder. Journal of Clinical Psychopharmacology, 31(5), 643–646. https://doi.org/10.1097/JCP.0b013e31822c6741
• Carvalho, A. F., Sharma, M. S., Brunoni, A. R., Vieta, E., & Fava, G. A. (2016). The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychotherapy and Psychosomatics, 85(5), 270–288. https://doi.org/10.1159/000447034
• Hasnain, M., & Vieweg, W. V. R. (2013). Weight considerations in psychotropic drug prescribing and switching. Postgraduate Medicine, 125(5), 117–129. https://doi.org/10.3810/pgm.2013.09.2706
• Cuomo, A., Ballerini, A., Bruni, A. C., Decina, P., Di Sciascio, G., Fiorentini, A., Scaglione, F., Vampini, C., & Fagiolini, A. (2019). Clinical guidance for the use of trazodone in major depressive disorder and concomitant conditions: Pharmacology and clinical practice. Rivista Di Psichiatria, 54(4), 137–149. https://doi.org/10.1708/3202.31796
• Tourian, K. A., Leurent, C., Graepel, J., & Ninan, P. T. (2010). Desvenlafaxine and Weight Change in Major Depressive Disorder. Primary Care Companion to The Journal of Clinical Psychiatry, 12(1), PCC.08m00746. https://doi.org/10.4088/PCC.08m00746blu
• McIntyre, R. S., Fayyad, R. S., Guico-Pabia, C. J., & Boucher, M. (2015). A Post Hoc Analysis of the Effect of Weight on Efficacy in Depressed Patients Treated With Desvenlafaxine 50 mg/d and 100 mg/d. The Primary Care Companion for CNS Disorders, 17(3), 10.4088/PCC.14m01741. https://doi.org/10.4088/PCC.14m01741
• Citrome, L. (2013). Levomilnacipran for major depressive disorder: A systematic review of the efficacy and safety profile for this newly approved antidepressant–what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International Journal of Clinical Practice, 67(11), 1089–1104. https://doi.org/10.1111/ijcp.12298
• Mago, R., Forero, G., Greenberg, W. M., Gommoll, C., & Chen, C. (2013). Safety and tolerability of levomilnacipran ER in major depressive disorder: Results from an open-label, 48-week extension study. Clinical Drug Investigation, 33(10), 761–771. https://doi.org/10.1007/s40261-013-0126-5
• Shi, Z., Atlantis, E., Taylor, A. W., Gill, T. K., Price, K., Appleton, S., Wong, M.-L., & Licinio, J. (2017). SSRI antidepressant use potentiates weight gain in the context of unhealthy lifestyles: Results from a 4-year Australian follow-up study. BMJ Open, 7(8), e016224. https://doi.org/10.1136/bmjopen-2017-016224
• Bet, P. M., Hugtenburg, J. G., Penninx, B. W. J. H., & Hoogendijk, W. J. G. (2013). Side effects of antidepressants during long-term use in a naturalistic setting. European Neuropsychopharmacology, 23(11), 1443–1451. https://doi.org/10.1016/j.euroneuro.2013.05.001
• Harvey, B. H., & Bouwer, C. D. (2000). Neuropharmacology of paradoxic weight gain with selective serotonin reuptake inhibitors. Clinical Neuropharmacology, 23(2), 90–97. https://doi.org/10.1097/00002826-200003000-00006
• Eder, J., Glocker, C., Barton, B., Sarisik, E., Popovic, D., Lämmermann, J., Knaf, A., Beqiri‐Zagler, A., Engl, K., Rihs, L., Pfeiffer, L., Schmitt, A., Falkai, P., Simon, M. S., & Musil, R. (2025). Who is at risk for weight gain after weight‐gain associated treatment with antipsychotics, antidepressants, and mood stabilizers: A machine learning approach. Acta Psychiatrica Scandinavica, 151(3), 231–244. https://doi.org/10.1111/acps.13684
• Simon, M. S., Barton, B., Zagler, A., Engl, K., Rihs, L., Glocker, C., & Musil, R. (2023). Lifestyle behaviors, metabolic disturbances, and weight gain in psychiatric inpatients treated with weight gain-associated medication. European Archives of Psychiatry and Clinical Neuroscience, 273(4), 839–851. https://doi.org/10.1007/s00406-022-01442-4
• Vandenberghe, F., Gholam-Rezaee, M., Saigí-Morgui, N., Delacrétaz, A., Choong, E., Solida-Tozzi, A., Kolly, S., Thonney, J., Gallo, S. F., Hedjal, A., Ambresin, A.-E., von Gunten, A., Conus, P., & Eap, C. B. (2015). Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. The Journal of Clinical Psychiatry, 76(11), e1417–1423. https://doi.org/10.4088/JCP.14m09358
• El Asmar, K., Fève, B., Colle, R., Trabado, S., Verstuyft, C., Gressier, F., Vievard, A., Haffen, E., Polosan, M., Ferreri, F., Falissard, B., Chanson, P., Becquemont, L., & Corruble, E. (2018). Early weight gain predicts later metabolic syndrome in depressed patients treated with antidepressants: Findings from the METADAP cohort. Journal of Psychiatric Research, 107, 120–127. https://doi.org/10.1016/j.jpsychires.2018.10.021
• Agarwal, S. M., Stogios, N., Ahsan, Z. A., Lockwood, J. T., Duncan, M. J., Takeuchi, H., Cohn, T., Taylor, V. H., Remington, G., Faulkner, G. E. J., & Hahn, M. (2022). Pharmacological interventions for prevention of weight gain in people with schizophrenia. The Cochrane Database of Systematic Reviews, 10(10), CD013337. https://doi.org/10.1002/14651858.CD013337.pub2
• Shokrgozar, S., Momeni, F., Zarabi, H., Abdollahi, E., Khalkhali, M., Najafi, K., Soleimani, R., Pazhooman, S., & Zare, R. (2024). Efficacy of metformin on the body mass index of patients under treatment with SSRI drugs referred to psychiatry clinics of Rasht. Heliyon, 10(15), e34320. https://doi.org/10.1016/j.heliyon.2024.e34320
• Menon, T., Lee, S., Gong, X. Y., Wong, S., Le, G. H., Kwan, A. T. H., Teopiz, K. M., Ho, R., Cao, B., Rhee, T. G., Jing Zheng, Y., Valentino, K., Lin, K., Vinberg, M., Lo, H. K. Y., & McIntyre, R. S. (2024). A systematic review on the efficacy of GLP-1 receptor agonists in mitigating psychotropic drug-related weight gain. CNS Spectrums, 1–7. https://doi.org/10.1017/S1092852924000531
• Gonzalez, C. L., Azim, S., & Miedlich, S. U. (2021). GLP-1 Analogs Are Superior in Mediating Weight Loss But Not Glycemic Control in Diabetic Patients on Antidepressant Medications: A Retrospective Cohort Study. The Primary Care Companion for CNS Disorders, 23(5), 20m02868. https://doi.org/10.4088/PCC.20m02868
• Siskind, D., Baker, A., Arnautovska, U., Warren, N., Russell, A., DeMonte, V., Halstead, S., Iyer, R., Korman, N., McKeon, G., Medland, S., Parker, S., Stedman, T., & Trott, M. (2025). Efficacy and safety of semaglutide versus placebo for people with schizophrenia on clozapine with obesity (COaST): A phase 2, multi-centre, participant and investigator- blinded, randomised controlled trial in Australia. The Lancet Psychiatry, 12(7), 493–503. https://doi.org/10.1016/S2215-0366(25)00129-4
• Kushner, R. F., Fink-Jensen, A., Frenkel, O., McGowan, B., Goldman, B., Overvad, M., & Wadden, T. (2024). Efficacy and safety of semaglutide 2.4 mg according to antidepressant use at baseline: A post hoc subgroup analysis. Obesity (Silver Spring, Md.), 32(2), 273–280. https://doi.org/10.1002/oby.23946
• Prasad, F., De, R., Korann, V., Chintoh, A. F., Remington, G., Ebdrup, B. H., Siskind, D., Knop, F. K., Vilsbøll, T., Fink-Jensen, A., Hahn, M. K., & Agarwal, S. M. (2023). Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin – a case series. Therapeutic Advances in Psychopharmacology, 13, 20451253231165169. https://doi.org/10.1177/20451253231165169
• McIntyre, R. S., Paron, E., Burrows, M., Blavignac, J., Gould, E., Camacho, F., & Barakat, M. (2021). Psychiatric Safety and Weight Loss Efficacy of Naltrexone/bupropion as Add-on to Antidepressant Therapy in Patients with Obesity or Overweight. Journal of Affective Disorders, 289, 167–176. https://doi.org/10.1016/j.jad.2021.04.017
• Minichino, A., Preston, T., Fanshawe, J. B., Fusar-Poli, P., McGuire, P., Burnet, P. W. J., & Lennox, B. R. (2024). Psycho-Pharmacomicrobiomics: A Systematic Review and Meta-Analysis. Biological Psychiatry, 95(7), 611–628. https://doi.org/10.1016/j.biopsych.2023.07.019
• Nikolova, V. L., Cleare, A. J., Young, A. H., & Stone, J. M. (2025). Exploring the mechanisms of action of probiotics in depression: Results from a randomized controlled pilot trial. Journal of Affective Disorders, 376, 241–250. https://doi.org/10.1016/j.jad.2025.01.153
• Mötteli, S., Vetter, S., Colla, M., & Hotzy, F. (2024). Are probiotics effective in reducing the metabolic side effects of psychiatric medication? A scoping review of evidence from clinical studies. Translational Psychiatry, 14(1), 26. https://doi.org/10.1038/s41398-024-02735-z
• Olanrewaju, K. R. (2012, September 25). A Randomised Controlled Study on the Effects of Endurance Exercise Therapy on Antidepressant Drugs Induced Changes in Body Composition. https://www.semanticscholar.org/paper/A-Randomised-Controlled-Study-on-the-Effects-of-on-Olanrewaju/bcae725d063150fc63e60ae84857e3b0d8996dd4#related-papers
• Cao, B., Xu, J., Li, R., Teopiz, K. M., McIntyre, R. S., & Chen, H. (2022). Interventions targeting comorbid depression and overweight/obesity: A systematic review. Journal of Affective Disorders, 314, 222–232. https://doi.org/10.1016/j.jad.2022.07.027